Citadel Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History
Bought
Maintained
Sold
Other funds holding IMDX
AIC
Citadel Advisors's IMDX Position: Q3 2026 in Review
Citadel Advisors opened a new position in Insight Molecular Diagnostics (IMDX) in Q3 2026: 33,511 shares worth $120K. The stake represents ﹤0.01% of the portfolio and ranks #12767 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in IMDX as recently as Q4 2025.
Citadel Advisors first reported a position in IMDX in Q1 2018 and has held it in 19 quarters since. The position peaked at $603K in Q1 2021. 44 funds tracked by Wall St. Rank hold IMDX as of Q3 2026.
- Citadel Advisors held 33,511 shares of Insight Molecular Diagnostics worth $120K as of Q3 2026.
- Insight Molecular Diagnostics was a new Citadel Advisors position in Q3 2026.
- Insight Molecular Diagnostics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #12767 holding.
- Citadel Advisors first reported a position in Insight Molecular Diagnostics in Q1 2018 and has held it in 19 quarters since.
- Citadel Advisors's Insight Molecular Diagnostics position peaked at $603K in Q1 2021.
- 44 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.